Ophthalmic Manifestations of HIV Infection
Digital Journal of Ophthalmology 2004
Volume 10, Number 3
October 29, 2004
This review is intended to describe the most common ophthalmic manifestations of HIV infection. It is estimated that more than 70% of adult AIDS patients will experience an ocular complication at some point of the disease. Orbital and adnexal manifestations include tumors of the periocular tissues and external infections. Anterior segment findings consist of keratitis, keratoconjunctivitis sicca, iridocyclitis, and other complications. Posterior segment findings include a HIV associated retinopathy and a number of opportunistic infections of the retina and choroid. HIV has also been related to neuro-ophthalmic manifestations such as visual field defects and papilledema.
The author performed a search of Medline, using PubMed. Search words included HIV, cytomegalovirus retinitis, retinal microvasculopathy, herpes zoster ophthalmicus, Kaposi`s sarcoma, immune recovery uveitis, orbital lymphoma, toxoplasmosis, herpes simplex virus, pneumocystis carinii, microsporidia, syphilis, molluscum contagiosum, ganciclovir and keratoconjunctivitis sicca. Articles were selected based on clinical importance. Additional references of key articles were also included. Articles were excluded if they had non-English abstracts.
HIV, Cytomegalovirus (CMV) retinitis, Retinal microvasculopathy, Herpes Zoster Ophthalmicus, Kaposi`s Sarcoma, Immune Recovery Uveitis, Toxoplasmic Retinochoroiditis
|The human immunodeficiency virus (HIV) infection has spread worldwide, with various adverse health and economic implications, particularly in the developing world.(1) A global summary of the HIV/AIDS epidemic from December 2003 by the Joint United Nations Programee on HIV/AIDS (UNAIDS) and World Health Organization (WHO) estimates that there are 40 million people worldwide living with HIV/AIDS. Approximately 5 million people were infected with HIV and there were about 3 million AIDS deaths in 2003.(2) At present, around 90% of HIV-infected persons live in developing countries, particularly those in sub-Saharan Africa and Southeast Asia.(2, 3) Unless a cure is found or life prolonging therapy can be made more widely available, the majority of people will remain suffering the profound impacts the disease has on their quality of life.(4) |
Numerous ophthalmic manifestations of HIV infection may involve the anterior or posterior segment of the eye. Since the first report of the ocular manifestations of AIDS by Holland et al. in 1982,(5, 6) subsequent studies have described several AIDS related conditions in the eye and orbit. 70–80% of adult AIDS patients will experience an ocular complication at some point of their illness.(5, 7) Orbital and adnexal findings include tumors of the periocular tissues and external infections. Anterior segment manifestations consist of keratitis, keratoconjunctivitis sicca, iridocyclitis, and other complications. Posterior segment findings include a HIV associated retinopathy and a number of opportunistic infections (OI) of the retina and choroid. HIV has also been related to neuro-ophthalmic manifestations, such as visual field defects, papilledema, and diplopia. The occurrence of ophthalmic complications associated with HIV infection is significantly lower in the pediatric age group. All patients with HIV disease should undergo routine ophthalmologic examinations, since proper diagnosis and treatment may help to maintain vision and prolong life. Some retinal OI may have a rapid and devastating course.
CD4+ T Lymphocyte proved to be a reliable predictor of ocular complications of HIV infection.(7, 8) The use of highly active antiretroviral therapy (HAART), which consists of a combination of nucleoside reverse transcriptase inhibitors, HIV protease inhibitors and non nucleoside reverse transcriptase inhibitors, has decreased plasma levels of HIV RNA and increased CD4+ T lymphocytes counts, improving the immune function of patients with HIV infection.(9, 10, 11) The clinical presentation of HIV related diseases may be modified by HAART, which has dramatically improved the prognosis of HIV infection. Before the introduction of HAART, patients with cytomegalovirus retinitis commonly had CD4+ counts less than 50 cells/µl with minimal ocular inflammation.(9) There are some reports of spontaneous resolution of cytomegalovirus retinitis in patients with increased CD4+ counts related to such therapy, although the recovery in T lymphocytes may take many months.(12, 13, 14) Nevertheless, substantial intraocular inflammation in patients with healed cytomegalovirus retinitis receiving HAART has been reported, which is known as immune recovery uveitis.(9,105)
|II – Orbital Manifestations|
Orbital manifestations of HIV infection are not seen very often. However, some cases of orbital cellulitis and orbital lymphoma have been reported. The cases of orbital cellulitis were related to Aspergillus infection most times, being treated with systemic antimicrobial drugs. Other organisms reported in the literature that caused orbital infections in patients with HIV include Rhizopus arrhizus, Toxoplasma gondii, and Pneumocystis carinii. Children may present with recurrent episodes of orbital/peri-orbital cellulitis.(15, 16) Primary non-Hodgkin`s lymphoma (NHL) of the orbit and ocular adnexa is a rare disease. It accounts for only 1% of all NHL. In general, the risk of developing NHL is higher in HIV infected patients. The reported cases of lymphoma responded well to radiotherapy. However, high doses may be correlated to late ocular complications.(17, 18)
III – Adnexal Manifestations
The most common adnexal manifestations in patients who have HIV infection are Kaposi`s sarcoma, herpes zoster ophthalmicus, moluscum contagiosum and conjunctival microvasculopathy.(19) Conjunctival squamous-cell carcinoma is a rare finding.
Kaposi`s sarcoma was a rare tumor. After the spread of HIV, the incidence markedly increased. It is a highly vascularized, painless mesenchymal tumor that affects the skin and mucous membranes and occurs in up to 25% of HIV infected patients. Around 20% of these patients have asymptomatic Kaposi`s sarcoma of the eyelids, conjunctiva and rarely the orbit.(7, 20)
However, a study by Biswas et al., who followed 100 HIV positive individuals in India, did not observe a single case of Kaposi`s sarcoma of the eye. The low prevalence of this tumor in India may be attributed to the lower proportion of cases associated with homosexual behavior in that country. DNA sequences of human herpes virus 8 have been detected in patients with Kaposi`s sarcoma either with or without HIV infection. The low incidence of human herpes virus 8 in India may also contribute to the low occurrence of this tumor in that country.(3, 21)
Kaposi`s sarcoma may present as purple papules in the eyelids, which may be either flat or slightly raised. Sometimes, these lesions are part of a multifocal presentation, which may include visceral involvement.(5, 22)
Conjunctival Kaposi`s sarcoma may occur in up to 1% of patients with HIV infection. The classic presentation is a reddish plaque that may mimic a subconjunctival hemorrhage or chalazion. This lesion is often located in the cul de sac. Even small lesions can cause important cosmetic and functional discomfort, which may be related to mass effect or secondary corneal changes.(5, 23)
Kaposi`s sarcoma does not invade the eye. Most lesions are slowly progressive and respond to systemic drug therapy (106). Radiation therapy may be effective when functional discomfort is reported. Nevertheless, it is expensive and can cause skin irritation and conjunctivitis. Doses of 20 Gy may be sufficient to produce shrinkage of the tumor. Excision and intralesional chemotherapy with vinblastine are other treatment options. If there is systemic involvement, systemic chemotherapy may be indicated.(7, 23)
There are some reports of regression in patients treated with HAART containing a protease-inhibitor. Saquinavir, indinavir, ritonavir and nelfinavir may affect angiogenesis, cell survival, tumor growth and invasion.(24)
Herpes Zoster Ophthalmicus
Reactivation of latent varicella zoster virus in the ophthalmic division of the trigeminal nerve causes herpes zoster ophthalmicus. The ophthalmic division branches into the lacrimal, nasociliary and frontal nerves. Involvement of the frontal nerve is common. When the nasociliary nerve is affected, the patients may present with vesicles at the tip of the nose, known as Hutchinson`s sign. Studies have shown ophthalmic involvement in 99% of patients with this sign.(25)
Herpes zoster occurs in patients with HIV infection as well as other patients with depressed cellular immunity such as lymphoma patients and patients receiving immunosuppressive therapy. Characteristic prodromal symptoms include headache, generalized malaise and fever.(26)
In younger individuals, it may be the initial manifestation of HIV infection.(27) Any patient younger than 50 years of age who presents with herpes zoster ophthalmicus is suspect of having HIV infection or any other immunosuppressive condition.(5, 28) A study by Hodge et al. showed a relative incidence risk ratio of 6.6/1 in HIV positive patients compared to HIV negative patients.(29)
Reports suggest that it affects 5–15% of HIV positive patients and may have a high rate of painful and sight threatening complications.(7, 27) Forty one percent of the patients studied by Lewallen in Malawi developed corneal perforation and seventeen percent of the patients studied by Sellitti et al. in Miami developed necrotizing retinitis. Ocular complications result from inflammation, nerve damage and tissue scarring.(30, 31)
Herpes zoster ophthalmicus presents as vesicobullous rash and may be associated with keratitis, scleritis, uveitis, retinitis or encephalitis.(27) The severity of the skin rash is an important prognostic parameter of subsequent ocular involvement.(32)
Significant entropion or trichiasis may result from herpes zoster, because the virus can cause permanent contraction scars of the deep dermal tissues of the eyelids.(25)
Patients should be treated with intravenous acyclovir (10 mg per kilogram of body weight three times a day for seven days) followed by an oral maintenance regimen (800 mg 3–5 times a day). Other options are famciclovir, which requires long term maintenance therapy, and valaciclovir.(7, 25)
Molluscum contagiosum is caused by a DNA poxvirus and affects the skin and mucous membranes as translucent papules with a central umbilication. In HIV patients it occurs commonly and lesions may become quite large and are often more numerous and more rapidly growing. Involvement of the eyelids may occur in up to 5% of HIV infected patients. They are usually multiple, bilateral, confluent, and tend to recur within 6 to 8 weeks after removal.(3)
Treatment options are cryotherapy, incision, curettage and excision. The use of podophyllotoxin cream as an adjunct to cryotherapy may be helpful. Lesions may recur particularly when CD4+ counts decrease.(33, 34)
Patients with HIV infection may present with asymptomatic microvascular changes, which is correlated with retinal microvasculopathy. The severity of the microvasculopathy has been correlated to increased zeta sedimentation ratios and fibrinogen levels.(35) Usually, no treatment is necessary. Those patients may have microaneurysms and segmental vascular dilatations and narrowings.(7) The cause of these vascular changes is not clear yet, but it is probably associated with the deposition of immune complexes related to HIV or the direct infection of HIV in the conjunctival vascular endothelium.(36)
Conjunctival Squamous-Cell Carcinoma
A study by Agaba in Uganda showed a correlation between an increase in cases of conjunctival squamous-cell carcinoma and HIV infection. These tumors have also been related to exposure to ultraviolet light and conjunctival papillomavirus infection and usually arise in the limbus of the eye.(37)
IV-Anterior Segment Disease
The anterior segment of the eyes (cornea, anterior chamber and iris) may also suffer changes related to HIV infection. Reports indicate that more than 50% of HIV infected patients have anterior segment manifestations.(38) Keratitis, keratoconjunctivitis sicca and iridocyclitis are among the most common complications in the anterior segment of the eyes. However, studies have shown no difference in the ocular flora between HIV-negative patients and patients with AIDS.(39)
Herpes Simplex Keratitis
Herpes simplex keratitis has been reported in AIDS patients, but whether there is an increase risk of this disease is still unknown. The infection has a predilection for the peripheral cornea and may cause corneal ulcerations, being usually painful. In general, the course of the disease is longer in AIDS patients and the rate of recurrences is also higher. It is associated with corneal scarring and iritis. The treatment of choice for epithelial keratitis consists of topical trifluridine six to eight times a day during the first several days. Orally administered acyclovir is also effective.(22, 40)
Varicella-Zoster Virus Keratitis
As mentioned before, the varicella zoster virus may be associated with keratitis in AIDS patients. The patients may present with elevated intraocular pressure. Commonly, the patients have herpes zoster ophthalmicus as well, although the dermatitis may be mild. As in herpes simplex keratitis, the course of the disease tends to be longer in AIDS patients. The treatment is similar to that of zoster ophthalmicus. (25, 28, 31)
Bacterial and Fungal Corneal Infections
Bacterial and fungal infections are generally more severe in HIV infected patients. Spontaneous fungal keratitis secondary to Candida albicans has been reported in patients with advanced HIV disease.(41) Candida species are particularly common in intravenous drugs users. Although uncommon, Microsporidia is associated with a bilateral diffuse punctate epithelial keratopathy and conjunctivitis. The treatment consists of oral itraconazole, oral albendazole or topical fumagillin.(42, 43, 44)
Posterior Intracorneal Infiltrates
Posterior intracorneal infiltrates have been reported in HIV infected hosts with concomitant cytomegalovirus retinitis and in children who have been treated with prophylactic rifabutin. Those infiltrates tend to be distributed primarily in the inferior cornea. The cause of those corneal infiltrates is still under investigation. They may be caused by direct deposition of immune complexes or viral particles, toxicity of medication or even the direct effect of opportunistic infections.(45)
More than 20% of patients with HIV infection may have keratoconjunctivitis sicca, also called dry eye syndrome, which results from deficiency of any of the tear film layers. Apparently, it is not related to CD4+ counts or associated with the severity of HIV.(46) Symptoms may include foreign body sensations, photophobia and decreased visual acuity. It is likely caused by both the destruction of primary and secondary lacrimal glands and inflammation mediated by the HIV virus. The treatment is based on the administration of artificial tears, often six to eight times a day, and lubricating ointments.(47)
An HIV infected patient complaining of photophobia and red eye may have iridocyclitis. This presentation requires a thorough ocular examination in order to rule out anterior or posterior segment infection.(5) It may be associated with retinal or choroidal infection with multiple opportunistic organisms, such as cytomegalovirus, herpes simples virus, varicella zoster virus, Candida species, Cryptococcus species, Toxoplasma gondii, Treponema pallidum and Mycobacterium species.(48)
In the differential diagnosis of acute iridocyclitis in a patient with AIDS, infection with syphilis or toxoplasmosis should always be considered. Immunocompromised hosts may have T. gondii infection bilaterally and have multiple infectious foci. Encysted T. gondii organisms have been found in an iris biopsy specimen from an AIDS patient presenting with iridocyclitis.(49)
PCR of the aqueous humor or vitreous of those patients may be used for identification of those organisms. Vitreous samples have a higher sensitivity.(49,107,108)
Some medications, such as rifabutin and cidofovir, have also been associated with iridocyclitis.(50, 51). Rifabutin is also related to ocular hypotony, and cidofovir may cause an endophthalmitis-like manifestation.
Iridocyclitis may also be associated with Reiter`s syndrome, which is defined by the classic triad of arthritis, urethritis, and conjunctivitis. This syndrome appears to be more common in patients with HIV infection.
The treatment of iridocyclitis depends on the specific infectious agent. In the cases associated with medications, the dose should be tapered or the drug should be discontinued. Topical corticosteroids are usually indicated, but must be used carefully whenever a infectious cause is suspected.(7)
V – Posterior Segment Disease
The posterior segment of the eye (retina, choroid and optic nerve head) is affected in more than 50% of AIDS patients. Those disorders may be either associated with infectious causes or non infectious causes. Decreased visual acuity, visual field defects and photopsias are among the most common symptoms.(97)
The microvascular changes in the retina are the most common retinal manifestations of HIV infection. Nevertheless, they are generally asymptomatic and transient. These changes may occur in up to 70% of AIDS patients at some point of the disease. The patients presenting with HIV retinopathy may have cotton-wool spots (CWS) in the retina, intraretinal hemorrhages, and retinal microaneurysms, especially when CD4+ T lymphocyte count is below 100 cells/mm3. Forty five percent of the patients with HIV related retinopathy have CD+ cell counts below 50 cells/mm3. (5, 52)
The CWS result from occlusion of precapillary arterioles, normally do no affect visual acuity and do not require treatment. They appear as small, white, superficial retinal opacities and are mainly localized on the posterior pole. Pathologically, the CWS are nerve fiber layer infarcts, related to accumulations of axoplasmic debris, subsequent to obstruction of axoplasmic flow.(53) They may represent an increased risk for cytomegalovirus (CMV) retinitis. The appearance of CWS is sometimes similar to CMV retinitis. CWS, however, tend to be smaller, do not progress, are not characteristically associated with retinal hemorrhage and resolve over weeks to months. AIDS patients with CWS should have close follow up.(52)
Intraretinal hemorrhages, including Roth`s spots, may be present in AIDS patients. They are commonly innocuous in the setting of HIV retinopathy and may occur within different layers of the retina.(5)
The pathogenesis of retinal microvasculopathy is probably similar to that of conjunctival microvasculopathy.(36) Hypothesis including hemorheologic abnormalities, like increased plasma viscosity and fibrinogen levels; circulating immune complexes and infectious damage of the retinal vasculature have been postulated.
Schmetterer and colleagues studied the ocular blood flow in patients infected with HIV. They detected a decreased macular leukocyte density in HIV infected persons. The study also suggested that abnormal retinal hemodynamics in this group may be involved in the pathogenesis of HIV-related microvasculopathy. No correlation between antiretroviral treatment and ocular blood flow parameters was found.(53)
Branch retinal artery and retinal vein obstructions have been seen in HIV infected patients. (54, 55) There are some reports of ischemic maculopathy associated with HIV infection, which can be severe, however the condition is apparently uncommon. The presence of opacification of the superficial retina, resulting in a cherry red spot, or intraretinal hemorrhages near the fovea may suggest the diagnosis, although some patients may not present with these findings. Bilateral involvement of the eyes, with an abrupt onset often occurs. Fluorescein angiography should be done on HIV infected patients with unexplained vision loss.(52)
A study by Cunningham and associates suggested the possibility that occult herpetic infection may be a contributing factor to ischemic maculopathy, as well as alterations in blood flow in the setting of microvascular abnormalities.(52)
Chronic Multifocal Retinal Infiltrates
Levinson and associates described a distinct syndrome in HIV infected subjects that was characterized by the presence of stable or slowly progressive multifocal peripheral infiltrates, often in association with inflammatory reactions in the vitreous humor and anterior chamber and lack of retinal necrosis. Those infiltrates do not seem to be related to drug toxicity or to opportunistic infections. Generally, they were round or irregular in shape, and typically less than 200 µm in the greatest dimension. Floaters were the most frequent complaint among the patients studied, followed by blurred vision. An auto immune phenomenon associated with immune response to the presence of HIV in the ocular tissue has been suspected to cause these inflammatory reactions. The long term effect of this syndrome on visual function remains unknown.(56)
Retinal infections in HIV infected patients may result from different pathogens, which may affect the retina at the same time.(57) Syphilis, candida, varicella-zoster, toxoplasmosis, herpes simplex and cytomegalovirus retinitis are among the most common ones. Although these infectious may also occur in immunocompetent hosts, the course tends to be longer in AIDS patients, and the rate of recurrences is also higher.
Varicella Zoster Virus and Herpes Simplex Retinitis
Varicella zoster virus has been associated with acute retinal necrosis, which affects 1–4% of HIV infected patients. It is characterized by peripheral retinal whitening, often accompanied by intraretinal hemorrhages associated with rapidly progressing necrosis over several days. Multifocal lesions are commonly seen. Retinal detachment with proliferative vitreoretinopathy as well as the involvement of the other eye may also occur.(58, 59) Central retinal vein occlusion as the initial presentation of herpes zoster ophthalmicus has also been reported.(60)
Although not frequently seen, herpes simplex virus has also been related to retinitis in HIV-positive patients. It has been associated with a rapid progressing visual loss.
The treatment for these two pathogens is normally long. Intravenous acyclovir and intraocular ganciclovir or foscarnet are commonly required.(59, 61), and long-term treatment with acyclovir prevents recurrences and is important in prophylaxis of the fellow eye (102,103)
Human cytomegalovirus (HCMV) is part of the beta subgroup of herpes viruses (Herpes viridae) and has strong species specificity. Although the infection with CMV is usually subclinical in immunocompetent hosts, there may be a life long persistence in 50–90% of the population. In immunocompromised hosts, such as patients infected with HIV, CMV may lead to several complications.(62, 63)
Cytomegalovirus (CMV) retinitis is the most common intraocular infection related to HIV infection, affecting around 25% of patients according to reports of the past decade and may cause progressive loss of vision and blindness.(5) The prevalence of visual impairment at the time of CMV retinitis diagnosis is high and is related to demographic characteristics.(64)
A study performed by Doan et al. showed a decrease in the incidence and prevalence of CMV retinitis after the advent of HAART. The relapses of CMV retinitis were less frequent (36% before HAART vs. 17% after HAART) and newly diagnosed CMV retinitis also decreased (6.1% before HAART to 1.2% after HAART). Remission durations from recurrent CMV retinitis have increased in patients receiving HAART, which is associated with decreased progression of retinal necrosis, and to lower risk of retinal detachment. Nevertheless, it does not restore the retina where such damage has already occurred.(65, 101)
Kempen et al. followed up 589 patients to evaluate the relationship of anti-CMV treatment and immune reconstitution in response to HAART on the mortality risk of patients with AIDS and CMV retinitis. The use of HAART reduced the risk of mortality by 81%; it was 96% lower for those who developed immune recovery and 49% lower for those who did not.(66)
Vision related quality of life (QOL) may still be compromised by CMV retinitis even when general health related QOL has improved in response to HAART. Therefore, prevention of CMV with anti-CMV medications may be warranted in high risk subjects.(67) The study by Doan et al. also suggested that a CD4+ cell count above 50 cells/mm3 or a low viral load does not fully protect from CMV disease. Immune response reconstitution may be only partial after HAART, because lack of pathogen specific CD4+ T cell response may persist even in the presence of a significant rise in the absolute CD4+ T cell counts.
Therefore, HIV-infected patients still require close ocular follow up even if they are being treated with HAART. Moreover, virologic resistance to HAART is becoming more frequent.(63, 65, 68)
Occasionally, HAART may cause vision loss via the mechanism of immune recovery uveitis.(67) It may be characterized by vitritis and optic disc and macular edema. Ocular neovascularization at the optic disc and the retinal periphery may also occur. Clinically important complications of immune-recovery uveitis may include cataract, epiretinal membrane formation, and cystoid macular edema. The mechanism of this condition remains unclear. Generally, substantial inflammation does not occur in eyes without prior CMV retinitis. Therefore, immune recovery uveitis may be caused by an immune response related to the persistence of CMV antigen in the eye. There are some reports showing that protease inhibitors may be associated with increased cytomegalovirus-specific lymphocyte proliferation and production of inflammatory cytokines.(9, 69) Song et al. showed that the risk of immune recovery uveitis was strongly correlated with prior use of cidofovir. It was not clear whether continuing noncidofovir anti-CMV therapy after immune recovery would reduce the risk of immune recovery uveitis.(70)
Recent reports show that CMV retinitis progression does not necessarily correlate with viral CMV loads, which is different from other CMV diseases, such as colitis and pneumonitis.(63)
Generally, CMV retinitis is characterized by hemorrhagic necrosis that may extend along the vascular arcade, as well as retinal whitening. (Figure 1b) The lesion tends to enlarge over time. The patients may also present with mild vitreal inflammation, anterior uveitis, and up to 5% of them may have involvement of the optic disc. Visual field loss, blurred vision and photopsias are common complaints by the patients.(7, 65)
The administration of systemic anti-CMV medication may prevent the occurrence of retinitis in the fellow eye.
The choice of a drug for the treatment of CMV retinitis should be based on the response to previous treatments, side effects as well as extension and severity of the disease.
In patients on chronic suppressive, maintenance therapy, CMV resistant to the treatment being used may develop. The identification of resistant virus in the blood or urine may have an association with adverse clinical outcomes of the CMV retinitis. There may be an increased risk of retinitis progression, as well as an increase in the amount of retinal area affected by CMV. Patients treated with ganciclovir implant alone probably have a higher rate of contralateral ocular or visceral disease than the ones receiving concomitant oral ganciclovir. The detection of CMV viral load in the blood or direct sequencing of blood specimens for CMV UL97 gene mutations may be important in the clinical setting, in order to determine the patients with resistant virus.(71)
Intravenous ganciclovir may be indicated when there is bilateral retinitis or when systemic treatment is required.(72) However, it may cause myelosuppression. Intravitreal ganciclovir injection is another option, though frequent injections are required and the fellow eye and distant organs are not protected. Standard doses range from 200 µg to 400 µg administered twice a week, for up to 3 weeks, followed by weekly maintenance injections. A report presented by Velez et al. suggested that higher doses of ganciclovir may be tolerated by the eye, and when associated with intravitreous foscarnet, they may be effective in controlling CMV retinitis in patients who do not respond to conventional treatment.(73, 74, 75) A controlled trial of valganciclovir by Martin et al. showed that it appears to be as effective as intravenous ganciclovir for induction treatment and is effective for long-term management of CMV retinitis.(76)
A ganciclovir intravitreal implant has been developed as a local treatment option that does not involve intravitreal injections and avoids systemic side-effects.(77) It is a non-erodable drug delivery device, which can provide therapeutic levels of ganciclovir to the posterior segment of the eye. The implants are designed to release ganciclovir over a period of months. Factors in the decision to use the ganciclovir implant include the location and severity of CMV retinitis, the patient's potential for immunologic improvement, and the risks and costs associated with implantation and concomitant oral ganciclovir therapy. Endophthalmitis is an uncommon complication of ganciclovir implant surgery.(78)
Intravenous foscarnet is another treatment option; nevertheless, it is associated with renal insufficiency.(72)
Combined intravenous ganciclovir and foscarnet offers the maximal protection of other eye and distant organs disease, though long daily infusions are required and the side effects are combined.(79)
In resistant cases, cidofovir therapy may be used. However, it has been associated with iritis and hypotonia and has the potential for nephrotoxicity, particularly in patients with history of kidney disease.(72, 79)
Other treatment alternatives are formivirsen injected into the vitreous or oral valganciclovir.(72)
Syphilis may affect the retina in HIV positive patients. As Treponema pallidum and HIV may be both transmitted sexually, it is not uncommon to detect both pathogens in the same patient. The retinitis is characterized by a deep yellow lesion. Retinal vasculitis and intraocular inflammation may be present. The diagnosis can be confirmed by the serum fluorescent treponema antibody absorption test (FTA ABS) and microhemagglutination assay (MHA-TP). When the diagnosis is confirmed, vigorous treatment should be started with 12-24 million units of intravenous penicillin G for 7-10 days.(80) Tetracycline, erythromycin and chloramphenicol are options for patients allergic to penicillin. Some authors believe that HIV positive patients may require maintenance therapy, because ocular symptoms may recur.(81, 82) Frequently, there may be atypical presentations of ocular syphilis in these patients, such as vitritis.(82)
Candidal endophthalmitis generally presents as a focal white infiltrate in the choroid, and may break through the retina into the vitreous. Usually, an overlying vitritis is present. Vitreous abscesses may also be seen. Once the diagnosis is confirmed, the patients should receive intravenous amphotericin.(5)
Around 1–2% of HIV infected patients may present with toxoplasmic retinochoroiditis. The prevalence of T. gondii infection varies between geographic regions and between population groups. Toxoplasmic retinochoroiditis still has a high prevalence in regions such as southern Brazil, where it may be as high as 8% (104). Ocular lesions may first develop many years after T. gondii infection. It is usually bilateral and presents multifocal sites of infection, which is not common in immunocompetent persons. Retinochoroidal scars and retinal hemorrhage may be absent. The appearance of the lesions varies with intensity of inflammation and duration of active retinal infection. Patients usually complain of seeing floaters, pain and decrease in visual acuity. Serologic studies should be performed; however they may be negative even in the presence of disease. PCR of the ocular fluid may be helpful in distinguishing between toxoplasmic retinochoroiditis and other ocular diseases.
The treatment consists of oral sulfadiazine, combined with pyrimethamine or clindamycin, or both. Trimethoprim-sulfamethoxazole may also be effective. Atovaquone may be used in immunocompromised patients who are at increased risk of bone marrow toxicity from sulfonamides. The patients may have fewer relapses when receiving maintenance sulfadiazine or trimethoprim-sulfamethoxazole. Recent studies have shown that a half-dosage regimen is also effective in preventing recurrences, which are believed to be caused either by the release of parasites from tissue cysts in the retina or dissemination of parasites from non-ocular sites. (83-86, 104)
Mycobacterium tuberculosis, Candida species, Cryptococcus species, Pneumocystis carinii and Treponema pallidum are among the most common entities related to infectious choroiditis, which is seen in less than 1% of HIV positive patients. Multiple, bilateral, round or ovoid, yellow-white lesions characterizes Pneumocystis carinii choroiditis. These lesions are usually slowly progressive and are not associated with iritis, vitritis, or vasculitis. The treatment is the same for Pneumocystis carinii pneumonia.(87-89, 98)
VI-Neuro-Ophthalmic Manifestations of HIV Infection
Optic neuropathies in HIV positive patients may be related to compression, infiltration, infection, vaso occlusion or inflammation. Cryptococcal meningitis and intracerebral toxoplasma cysts, which are intracranial manifestations associated with HIV, can affect the eyes, causing nerve palsies. Neuro ophthalmic complications of HIV have also been reported in the absence of associated opportunistic infections. Optic neuritis associated with a multiple sclerosis like illness in the presence of HIV has also been described.(90) Other neuro ophthalmic complications are visual field defects, papilledema, secondary to elevated intracranial pressure and ocular motility disorders, occurring in up to 15% of HIV-infected patients.(5, 91) HIV may also cause diplopia due to palsies of cranial verves III, IV, and VI. Neurosyphilis, progressive multifocal leukoencephalopathy (PML), which is caused by JC polyomavirus, meningeal and parenchymal lymphoma, and intracerebral infection with herpes virus have also been related to neuro-ophthalmic manifestations. The diagnosis of PML should be considered in immunocompromised patients with neuro-opthalmic findings, especially in those presenting with homonymous hemianopia and nystagmus.(92) Herpes virus may present with papilledema and extraocular muscle palsies.
Microvascular oculomotor nerve palsies may occur in association with HIV. Premature atherosclerosis is commonly seen in HIV-infected patients due to an unknown mechanism.(93)
Lumbar puncture and magnetic resonance imaging are usually required in order to determine the pathogen causing the neuro ophthalmic symptoms, and to start the proper treatment. Generally, intracranial lymphoma is treated with radiation and chemotherapy. The infections are treated with specific antimicrobial drugs.(7)
The optic nerve may be affected by HIV due to direct infection. Another explanation is related to HIV viral proteins. Tat and gp 120, which are viral proteins, may have direct and indirect toxic effects on neurons. Moreover, HIV may induce the production of TNF alpha, IL I and arachidonic acid metabolites, which may cause neurotoxicity. Some studies suggest that non-nucleoside and nucleoside reverse transcriptase inhibitors (NRTIs) may impair mithocondrial function.(90)
HIV infected persons differ in measures of the retinal nerve thickness, cross sectional area and cup shape. Most defects are found in patients with associated CMV retinitis. A study by Plummer et al. demonstrated that HIV positive patients without CMV retinitis still have statistically significantly abnormal measures in retinal fiber layer thickness, rim volume, retinal fiber layer area and disk area, indicating that there may be destruction of the retina as a complication of HIV infection, with or without CMV retinitis.(94, 95)
VII – Ocular Manifestations in the Pediatric Group
The first reports of HIV infection in children are from 1982, after the description of the disease in intravenous drug abusers and homosexual men.(96) A global summary of HIV/AIDS epidemic dating from December 2003 from UNAIDS/WHO estimates that there are 2.5 million children under 15 years worldwide living with HIV/AIDS, and 700,000 were newly infected with HIV in 2003. Approximately 500,000 children died from the disease in 2003.(2)
The most frequent mode of transmission of HIV in the pediatric group is mother to child transmission. The incubation period tends to be shorter in children. Some bacterial infections are more common in this age group than in adults, whereas cryptococcosis and toxoplasmosis are less frequent. Therefore, HIV infection may be different in children in several ways.
The occurrence of ophthalmic complications associated with HIV infection is significantly lower in the pediatric group. The first reports of eye complications in children related to HIV infection are from 1982. Kaposi`s sarcoma, as well as CMV retinitis are not as common as in the adult population. The reason for this fact is still unclear, but may be related to an altered immune response to HIV in children. The most frequent manifestation in the pediatric group is dry eye syndrome, which occurs in approximately 20% of patients. Some authors described perivasculitis of the peripheral fundus vessels as a common finding in children with AIDS.(96, 99)
A report by Kestelyn et al., who followed 162 HIV infected children in Africa, showed a high incidence (38%) of perivasculitis and/or sheathing of the peripheral retinal vessels. Bilateral involvement was very common and the severity tended to be symmetrical. Veins were affected more often than arteries. The lesions frequently originated in the periphery, sometimes extending towards the posterior pole without invading it. The authors also described a possible link between lymphocitic interstitial pneumonia, parotitis, lacrimal gland involvement, and perivasculitis of the retinal vessels as the expression of the same immunopathological process in different sites. CMV retinitis and cotton-wool spots, the most frequent ocular finding in adult HIV infection, as well as external lesions, such as herpes zoster ophthalmicus and Kaposi`s sarcoma of the eyelids were rare in the African pediatric group.(96)
Purdy et al. reported three cases of bilateral progressive outer retinal necrosis due to varicella-zoster virus in children with HIV infection. All three lost vision in both eyes.(100)
|The author wishes to thank the National Eye Institute, National Institutes of Health for providing the clinical pictures and the anonymous reviewers for their constructive comments.|
|1-Sleasman JW, Goodenow MM. HIV-1 infection. J Allergy Clin Immunol 2003; 111:582–92. |
2-UNAIDS/WHO report on the global HIV/AIDS epidemic. Geneva: World Health Organization, December 2003.
3-Biswas J, Madhavan HN, George AE, et al. Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol 2000; 129:9–15.
4-Preliminary development of the World Health Organization's Quality of Life HIV instrument (WHOQOL-HIV): analysis of the pilot version. Social Science & Medicine, In Press, Corrected Proof, Available online 27 March 2003, WHOQOL HIV Group.
5-Sarraf D, Ernest JT. AIDS and the Eyes. The Lancet 1996; 348:525–28.
6-Holland GN, Gottlieb MS, Yee RD, et al. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol 1982; 93:393–402.
7-Cunningham ET Jr, Margolis TP. Ocular manifestations of HIV infection. N Engl J Med 1998; 339:236–44.
8-Turner BJ, Hecht FM, Ismail RB. CD4+ T-Lymphocyte measures in the treatment of individuals infected with human immunodeficiency virus type 1: a review for clinical practitioners. Arch Intern Med 1994; 154:1561–73.
9-Robinson MR, Reed G, Csaky KG, et al. Immune recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol 2000; 130:49–56.
10-Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine: AIDS Clinical Trials Group. N Engl J Med 1996; 334:1011–17.
11-Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trial Group 320 Study Team. N Engl J Med 1997; 337:725–33.
12-Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA1997; 277:1519–20.
13-Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997; 124:199–205.
14-Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112–6.
15-Kronish JW, Johnson TE, Gilberg SM, et al. Orbital infections in patients with human immunodeficiency virus infection. Ophthalmology 1996; 103:1483–92.
16-Hoare S. HIV infection in children––impact upon ENT doctors. Int J Pediatr Otorhinolaryngol 2003; 67:S85-90.
17-Antle CM, White VA, Horsman DE, Rootman J. Large cell orbital lymphoma in a patient with acquired immune deficiency syndrome: case report and review. Ophthalmology 1990; 97:1494–8.
18-Martinet S, Ozsahin M, Belkacemi Y, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. International Journal of Radiation Oncology Biology Physics 2003; 55:892-98.
19-Akduman L, Pepose JS. Anterior segment manifestations of acquired immunodeficiency syndrome. Semin Ophthalmol 1995; 10:111–8.
20-Tschachler E, Bergstresser PR, Stingl G. HIV related skin diseases. The Lancet 1996; 348:659–63.
21-Moore PS, Chang Y. Detection of herpes virus like DNA sequences in Kaposi sarcoma in patients with and without HIV infection. N Engl J Med 1995; 32:1181–85.
22-Palestine AG, Palestine RF. External ocular manifestations of the acquired immunodeficiency syndrome. Ophthalmol Clin North Am 1992; 5:319–24.
23-Kirova YM, Belembaogo E, Frikha H, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. Radiother Oncol 1998; 46:19-22.
24-Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4:537-47.
25-Looney BD. Herpes zoster ophthalmicus. Clinical Eye and Vision Care 1997; 9:203-11.
26-Wang AG, Liu JH, Hsu WM, et al. Optic Neuritis in Herpes Zoster Ophthalmicus. Jpn J Ophthalmol 2000; 44:550-54.
27-Margolis TP, Milner MS, Shama A, et al. Herpes Zoster Ophthalmicus in Patients With Human Immunodeficiency Virus Infection. Am J Ophthalmol 1998; 125:285–91.
28-Karbassi M, Raizman MB, Schuman JS. Herpes zoster ophthalmicus. Surv Ophthalmol 1992; 36:395–410.
29-Hodge WG, Seiff SR, Margolis TP. Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative: Historical image. Ophthalmology 1998; 105:895-900.
30-Lewallen S. Herpes zoster ophthalmicus in Malawi. Ophthalmology 1994; 101: 1801—04.
31-Sellitti TP, Huang AJW, Schiffman J, Davis JL. Association of herpes zoster ophthalmicus with acquired immunodeficiency syndrome and acute retinal necrosis. Am J Ophthalmol 1993; 116:297–301.
32-Zaal MJ, Volker-Dieben HJ, D'Amaro J. Prognostic value of Hutchinson's sign in acute herpes zoster ophthalmicus. Graefes Arch Clin Exp Ophthalmol 2003; 241:187-91.
33-Bardenstein DS, Elmets C. Hyperfocal cryotherapy of multiple Molluscum contagiosum lesions in patients with the acquired immunodeficiency syndrome. Ophthalmology 1995; 102:1031–4.
34-Chard SC, Worlidge PJ, Holder MA, et al. New treatment for molluscum contagiosum in patients with HIV infection. J Eur Acad Dermatol Venereol 1997; 9:S148.
35-Tufail A, Meiselman HJ, Engstrom RE, et al. Hemorheologic abnormalities and ophthalmic disease in patients with human immunodeficiency virus infection. Biorheology 1995; 32:336.
36-Engstrom RE Jr, Holland GN, Hardy WD, Meiselman HJ. Hemorheologic abnormalities in patients with human immunodeficiency virus and ophthalmic microvasculopathy. Am J Ophthalmol 1990; 109:153–61.
37-Agaba CA. Conjunctival squamous-cell carcinoma associated with HIV infection in Kampala, Uganda. The Lancet 1995; 345:695-96.
38-Akduman L, Pepose JS. Anterior segment manifestations of acquired immunodeficiency syndrome. Semin Ophthalmol 1995; 10:111–8.
39-Gritz DC, Scott TJ, Sedo SF, et al. Ocular flora of patients with AIDS compared with those of HIV-negative patients. Cornea 1997; 16:400-5.
40-Kaufman HE. Treatment of viral diseases of the cornea and external eye. Prog Retin Eye Res 2000; 19:69-85.
41-Parrish CM, O'Day DM, Hoyle TC. Spontaneous fungal corneal ulcer as an ocular manifestation of AIDS. Am J Ophthalmol 1987; 104:302–303.
42-Hemady RK. Microbial keratitis in patients infected with the human immunodeficiency virus. Ophthalmology 1995; 102:1026–30.
43-Lowder CY, McMahon JT, Meisler DM, et al. Microsporidial keratoconjunctivitis caused by Septata intestinalis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol 1996; 121:715–7.
44-Chan CM, Theng JT, Li L, Tan DT. Microsporidial keratoconjunctivitis in healthy individuals: A case series. Ophthalmology 2003; 110:1420-25.
45-Chu DS, Zaidman GW, Meisler DM, et al. Human immunodeficiency virus positive patients with posterior intracorneal precipitates. Ophthalmology 2001; 108: 1853–57.
46-Geier SA, Libera S, Klauss V, Goebel FD. Sicca syndrome in patients infected with the human immunodeficiency virus. Ophthalmology 1995; 102:1319-24.
47-Lucca JA, Farris RL, Bielory L, Caputo AR. Keratoconjunctivitis sicca in male patients infected with human immunodeficiency virus type 1. Ophthalmololgy 1990; 97: 1008–10.
48-Rosberger DF, Heinemann MH, Friedberg DN, Holland GN. Uveitis Associated With Human Immunodeficiency Virus Infection. Am J Ophthalmol 1998; 125:301–05.
49-Parra JC, Lopis MDL, Cordoba J, et al. Acute iridocyclitis in a patient with AIDS diagnosed as toxoplasmosis by PCR. Ocul Immunol Inflamm 2000; 8: 127–30.
50-Nichols CW. Mycobacterium avium complex infection, rifabutin, and uveitis – is there a connection? Clin Infect Dis 1996; 22: Suppl. 1:S43–S47.
51-Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733–7.
52-Cunningham ET Jr, Levinson RD, Jampol LM, et al. Ischemic maculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 2001; 132:727–33.
53-Ruhswurm ID, Kiss B, Rainer G, et al. Ocular blood flow in patients infected with human immunodeficiency virus. Am J Ophthalmol 2001; 132:720–26.
54-Teich SA, Sonnabend J. Central retinal vein occlusion in a patient with AIDS. Arch Ophthalmol 1988; 106:1508–1509.
55-Yassur Y, Biedner B, Fabrikant M. Branch retinal artery occlusion in acquired immunodeficiency syndrome prodrome. Ann Ophthalmol 1988; 20:191–92.
56-Levinson RD, Vann R, Davis JL, et al. Chronic Multifocal Retinal Infiltrates in Patients Infected With Human Immunodeficiency Virus. Am J Ophthalmol 1998; 125:312–24.
57-Rummelt V, Rummelt C, Jahn G, et al. Triple retinal infection with human immunodeficiency virus type 1, cytomegalovirus, and herpes simplex virus type 1: light and electron microscopy, immunohistochemistry and in situ hybridization. Ophthalmology 1994; 101:270–79.
58-Freeman WR, Thomas EL, Rao NA, et al. Demonstration of herpes group virus in acute retinal necrosis syndrome. Am J Ophthalmol 1986; 102:701–09.
59-Moorthy RS, Weinberg DV, Teich SA, et al. Management of varicella zoster retinitis in AIDS. Br J Ophthalmol 1997; 81:189–94.
60-Biswas J, Deka S, Padmaja S, et al. Central retinal vein occlusion due to herpes zoster as the initial presenting sign in a patient with acquired immunodeficiency syndrome (AIDS). Ocul Immunol Inflamm 2001; 9:125-30.
61-Cunningham ET Jr, Short GA, Irvine AR, et al. Acquired immunodeficiency syndrome associated herpes simplex virus retinitis: clinical description and use of a polymerase chain reaction-based assay as a diagnostic tool. Arch Ophthalmol 1996; 114:834–40.
62-Markomichelakis NN, Canakis C, Zafirakis P, et al. Cytomegalovirus as a cause of anterior uveitis with sectoral iris atrophy. Ophthalmology 2002; 109:879–82.
63-Scholz M, Doerr HW, Cinatl J. Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. Trends Microbiol 2003; 11:171–78.
64-Kempen JH, Jabs DA, Wilson LA, et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 2003; 121:466-76.
65-Doan S, Cochereau I, Guvenisik N, et al. Cytomegalovirus retinitis in HIV infected patients with and without highly active antiretroviral therapy. Am J Ophthalmol 1999; 128: 250–51.
66-Kempen JH, Jabs DA, Wilson LA, et al. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 2003; 37:1365-73.
67-Kempen JH, Martin BK, Wu AW, et al. The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2003; 110:987–95.
68-Lilleri D, Piccinini G, Baldanti F, et al. Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. J Clin Virol 2003; 26:95–100.
69-Robinson MR, Csaky KG, Lee SS, et al. Fibrovascular changes misdiagnosed as cytomegalovirus retinitis reactivation in a patient with immune recovery. Clin Infect Dis 2004; 38:139-41.
70-Song MK, Azen SP, Buley A, et al. Effect of anti- cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 2003; 136:696-702.
71-Jabs DA, Martin BK, Forman MS, et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol 2003; 135:26–34.
72-2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. November 28, 2001. Available at: http://www.aidsinfo.nih.gov. Accessed March 19, 2004.
73-Velez G, Roy CE, Whitcup SM, et al. High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis. Am J Ophthalmol 2001; 131:396–97.
74-Heinemann M-H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989; 107:1767–72.
75-Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997; 337:83–90.
76-Martin DF, Sierra-Madero J, Walmsley S, et al. A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis. N Engl J Med 2002; 346:1119-1126.
77-Kunou N, Ogura Y, Yasukawa T, et al. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release 2000; 68:263–71.
78-Shane TS, Martin DF, Endopthalmitis-Gancioclovir Implant Study Group. Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 2003; 136:649-54.
79-Holland GN, Tufail A, Jordan MC. Cytomegalovirus diseases. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular infection & immunity. St. Louis: Mosby Year Book, 1996:1088–120.
80-McLeish WM, Pulido JS, Holland S, et al. The ocular manifestations of syphilis in the human immunodeficiency virus type 1 infected host. Ophthalmology 1990; 97:196–203.
81-Browning DJ. Posterior segment manifestations of active ocular syphilis, their response to a neurosyphilis regimen of penicillin therapy, and the influence of human immunodeficiency virus status on response. Ophthalmology 2000; 107:2015–23.
82-Kuo IC, Kapusta MA, Rao NA. Vitritis as the Primary Manifestation of Ocular Syphilis in Patients With HIV Infection. Am J Ophthalmol 1998; 125:306-11.
83-Accorinti M, Pivetti-Pezzi P, Tamburi S, et al. Toxoplasmic ocular infection in patients with AIDS. VII International Conference on AIDS. Florence 1991; 7: M. B. 83.
84-Kopec R, De Caro G, Chapnick E, et al. Prophylaxis for ocular toxoplasmosis. Clin Infect Dis 2003; 37:e147-8.
85-Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 2003; 136:973-88.
86-Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol 2004; 137:1-17.
87-Freeman WR, Gross JG, Labelle J, et al. Pneumocystis carinii choroidopathy. A new clinical entity. Arch Ophthalmol 1989; 107:863–867.
88-Morinelli EN, Dugel PU, Riffenburgh R, Rao NA. Infectious multifocal choroiditis in patients with acquired immune deficiency syndrome. Ophthalmology 1993;100: 1014 21.
89-Shami MJ, Freeman W, Friedberg D, et al. A multicenter study of pneumocystis choroidopathy. Am J Ophthalmol 1991;112:15-22.
90-Lee WB, O’Halloran HS, Berger JR. Human immunodeficiency virus and bilateral optic atrophy. Neuro Ophthalmology 2000; 24:461–67.
91-Miller NR. Walsh and Hoyt`s clinical neuro-ophthalmology. 4th ed., Vol. 5, Part 2. Baltimore: Williams & Wilkins, 1995:4107–56.
92-Wein F, Francis GS, Gans MS, et al. Neuro-ophthalmic findings in progressive multifocal leukoencephalopathy. Can J Ophthalmol 1998; 33:270-75.
93-Moulignier A, Laloum L, Chauveau E, et al. HIV-1 related ischaemic trochlear nerve palsy. J Neurol 2003; 250:108-9.
94-Malessa R, Agelink MW, Diener HC. Dysfunction of visual pathways in HIV 1 infection. J Neurol Sci 1995; 130:82–87.
95-Plummer DJ, Bartsch DUG, Azen SP, et al. Retinal nerve fiber layer evaluation in human immunodeficiency virus–positive patients. Am J Ophthalmol 2001;131:216-22.
96-Kestelyn P, Lepage P, Karita E, Van de Perre P. Ocular manifestations of infection with the human immunodeficiency virus in an African pediatric population. Ocul Immunol Inflamm 2000; 8: 263–73.
97-Caskey PJ, Ai E. Posterior segment manifestations of AIDS. Ophthalmol Clin North Am 1990; 3:396.
98-Sheu SJ, Shyu JS, Chen LM, et al. Ocular manifestations of tuberculosis. Ophthalmology 2001; 108:1580–85.
99-Dennehy PJ, Warman R, Flynn JT, et al. Ocular manifestations in pediatric patients with acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107:978–82.
100-Purdy KW, Heckenlively JR, Church JA, Keller MA. Progressive outer retinal necrosis caused by varicella-zoster virus in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2003; 22:384-86.
101-Vrabec TR. Posterior segment manifestations of HIV/AIDS. Surv Ophthalmol 2004; 49:131-57.
102-Wilhelmus KR, Beck RW, Moke PS, et al. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 1998;339:300-6.
103-Uchoa UB, Rezende RA, Carrasco MA. Long-term oral acyclovir effective in decreasing herpes simplex viral recurrences. Arch Ophthalmol 2003;121:1702-4.
104-Moraes HV. Ocular manifestations of HIV/AIDS. Curr Opin Ophthalmol 2002;13:397-403.
105-Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179:697-700.
106-Shuler JD, Holland GN, Miles SA, et al. Kaposi sarcoma of the conjunctiva and eyelids associated with the acquired immunodeficiency syndrome. Arch Ophthalmol 1989;107:858-62.
107-Moshfeghi DM, Dodds EM, Couto CA. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmol 2004;111:716-25.
108-Montoya JG, Parmley S, Liesenfeld O, et al. Use of polymerase chain reaction for diagnosis of ocular toxoplasmosis. Ophthalmol 1999;106:1554-63.
109-Martin DF, Dunn JP, David JL, et al. Use of ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. Am J Ophthalmol 1999;127:329-39.
|Figure 1a. Normal fundus|
Figure 1b. Fundoscopic changes seen in CMV retinitis
Fundoscopic changes seen in CMV retinitis